Form D · Pharmaceuticals

TrialScope, Inc.

Jersey City, NJ · CIK 0001610301

Offering snapshot reported Sep 17, 2018 · SEC filing

Reported sold
$4M
Offering amount: $4.5M
Investors reported
5
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Sep 5, 2018
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Sep 17, 2018Initial$4,000,000No comparison5SEC filing
Apr 25, 2017Initial$3,565,000No comparison6SEC filing
Jun 10, 2014Initial$10,200,000No comparison4SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-321539

Source: Form D, filed Sep 17, 2018. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Richard Aguinaldo Executive
Michael Balmuth Director
Larry Berran Director
Michael A Di Piano Director
E. Michael Forgash Director, Executive
Mark Heinold Director, Executive
James Hill Director
Eric Jensen Director
Michael Kopelman Director
Jeffrey Kozloff Director, Executive
Marc Lederman Director
Chris Noe Director
Christopher Noe Director
Matthew Patras Executive
Charles Saldarini Director
Joe Stauffer Director
James C. Walker Director
Jim Walker Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
Harborside 5 185 Hudson Street, Suite 2900
Jersey City, NJ, 07311